Baxter International Inc risk profile
60 Stretched several inputs deteriorating together
Measured 21 October 2026 from BAX's filed statements. Recomputed nightly.
60 (Stretched), driven by Competitive position at 80, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 35 | Normal | Stable | One-year price volatility — 42.8% |
| Operating pressure | 31 | Normal | Easing | Costs outgrowing revenue — +4.7 percentage points |
| Cash conversion | 53 | Elevated | Worsening | Capital spending against operating cash — 0.61x |
| Leverage and coverage | 75 | Stretched | Easing | Net debt to EBITDA — 11.10x |
| Competitive position | 80 | Acute | Stable | Operating-margin gap against peers — -14.6 percentage points |
| Concentration | 54 | Elevated | Stable | Geographic concentration — 4,217 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Baxter International Inc